Search - tctmd.com

Displaying 301 - 320 of 1379

Sort: Relevancy | Date

Presentation TCT 2023

Hypertension Care Pathway with uRDN: Experiences from Clinical Trials

Presenter: NULL

October 25, 2023

Presentation TCT 2023

A High Standard of Clinical Evidence: Recent Key Milestones

Presenter: NULL

October 25, 2023

Presentation TCT 2023

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

Presenter: Hamza Naveed

October 25, 2023

Presentation TCT 2023

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Michel Azizi

October 25, 2023

Presentation TCT 2023

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

Presenter: Victor Zeijen

October 25, 2023

Presentation TCT 2023

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

Presenter: Karl Fengler

October 25, 2023

Presentation TCT 2023

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Presenter: Anna Subbotina

October 25, 2023

Presentation TCT 2023

Clinician Perspectives

Presenter: Naomi Fisher

October 24, 2023

Presentation TCT 2023

Industry Perspectives

Presenter: Sandeep Brar

October 24, 2023

Presentation TCT 2023

Trialist Perspectives

Presenter: Felix Mahfoud

October 24, 2023

News Daily News

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Yael L. Maxwell

October 12, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Conference News EACTS 2023

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

Michael O'Riordan

October 05, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Michael O'Riordan

September 29, 2023

News Daily News

Slight Declines in Kidney Function Portend CV Trouble for Young Adults

Todd Neale

September 18, 2023

News Daily News

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Michael O'Riordan

September 15, 2023

News Daily News

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

Todd Neale

September 13, 2023

News Daily News

‘Astonishing’ Rates of CVD Linked to Lead Exposure

Caitlin E. Cox

September 13, 2023

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

Todd Neale

September 12, 2023

Advertisement

Hypertension Care Pathway with uRDN: Experiences from Clinical Trials

A High Standard of Clinical Evidence: Recent Key Milestones

TCT 726: Efficacy of Renal Denervation and antihypertensives in patients with resistant hypertension: A systematic review and Network meta analysis

TCT 398: Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Six-Month Results Following Blinded Medication Titration in the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

TCT 210: Long-term Safety and Efficacy of Endovascular Ultrasound Renal Denervation in Resistant Hypertension: 8-year results from the ACHIEVE study

TCT 207: Prediction of Six- and Twelve-Months Blood Pressure Results After Renal Denervation for Arterial Hypertension

TCT 152: Echocardiographic Findings Following Renal Sympathetic denervationfor treatment resistant hypertension, The ReShape CV-risk study.

Clinician Perspectives

Industry Perspectives

Trialist Perspectives

Pooled Cohort Equations Work in Real-world Patients, Even Outliers

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

SWEDEHEART Hints at Mortality Benefit With Statins After SAVR

October 2023 News Roundup

PET-Guided Strategy Lowers Risk, Boosts Outcomes in Stable CAD: CENTURY

Slight Declines in Kidney Function Portend CV Trouble for Young Adults

European Regulators Investigating CV Safety of Weight-Loss Drug Mysimba

Prescribing a Generic for CVD? Plan, Drug Type, and Condition Impact Availability

‘Astonishing’ Rates of CVD Linked to Lead Exposure

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content